33362607|t|The Relationship Between Serum Cytokine Levels and the Degree of Psychosis and Cognitive Impairment in Patients With Methamphetamine-Associated Psychosis in Chinese Patients.
33362607|a|Background: Cytokine levels can be changed in methamphetamine (METH) use disorders (MUDs) and primary psychosis. The present study assessed serum levels of some kinds of interleukins (ILs) in METH-associated psychosis (MAP) and their relationships with psychotic symptoms and cognitive dysfunction. Methods: Serum IL-2R, IL-6, IL-8, and IL-10 levels were examined by chemiluminescence assays in MAP patients (n = 119) and healthy controls (n = 108). The Positive and Negative Syndrome Scale (PANSS) and Montreal Cognitive Assessment (MOCA) were administered. Results: Serum levels of IL-6 and IL-8 were significantly increased in MAP patients (all p < 0.05). There was a negative relationship between IL-2R levels and PANSS positive (P) subscale scores (r = -0.193, p = 0.035). IL-6, IL-8 and IL-10 levels were all negatively correlated with the naming, delayed recall and orientation subscores on the MOCA (r = -0.209, p = 0.022; r = -0.245, p = 0.007; r = -0.505, p < 0.001, respectively). Conclusions: Our results indicate that immune disturbances are related to MAP and that IL-2R, IL-6, IL-8, and IL-10 are associated with the severity of psychotic symptoms and cognitive function impairment.
33362607	65	74	Psychosis	Disease	MESH:D011618
33362607	79	99	Cognitive Impairment	Disease	MESH:D003072
33362607	103	111	Patients	Species	9606
33362607	117	132	Methamphetamine	Chemical	MESH:D008694
33362607	144	153	Psychosis	Disease	MESH:D011618
33362607	165	173	Patients	Species	9606
33362607	221	236	methamphetamine	Chemical	MESH:D008694
33362607	238	242	METH	Chemical	MESH:D008694
33362607	244	257	use disorders	Disease	MESH:D000437
33362607	259	263	MUDs	Disease	MESH:D007922
33362607	277	286	psychosis	Disease	MESH:D011618
33362607	367	371	METH	Chemical	MESH:D008694
33362607	383	392	psychosis	Disease	MESH:D011618
33362607	394	397	MAP	Disease	MESH:D011618
33362607	428	446	psychotic symptoms	Disease	MESH:D011618
33362607	451	472	cognitive dysfunction	Disease	MESH:D003072
33362607	489	494	IL-2R	Gene	3559
33362607	496	500	IL-6	Gene	3569
33362607	502	506	IL-8	Gene	3576
33362607	512	517	IL-10	Gene	3586
33362607	570	573	MAP	Disease	MESH:D011618
33362607	574	582	patients	Species	9606
33362607	759	763	IL-6	Gene	3569
33362607	768	772	IL-8	Gene	3576
33362607	805	808	MAP	Disease	MESH:D011618
33362607	809	817	patients	Species	9606
33362607	876	881	IL-2R	Gene	3559
33362607	953	957	IL-6	Gene	3569
33362607	959	963	IL-8	Gene	3576
33362607	968	973	IL-10	Gene	3586
33362607	1206	1225	immune disturbances	Disease	MESH:D007154
33362607	1241	1244	MAP	Disease	MESH:D011618
33362607	1254	1259	IL-2R	Gene	3559
33362607	1261	1265	IL-6	Gene	3569
33362607	1267	1271	IL-8	Gene	3576
33362607	1277	1282	IL-10	Gene	3586
33362607	1319	1337	psychotic symptoms	Disease	MESH:D011618
33362607	1342	1371	cognitive function impairment	Disease	MESH:D003072
33362607	Positive_Correlation	MESH:D008694	MESH:D003072
33362607	Association	MESH:D003072	3576
33362607	Association	MESH:D003072	3569
33362607	Positive_Correlation	MESH:D011618	3569
33362607	Positive_Correlation	MESH:D011618	3576
33362607	Positive_Correlation	MESH:D008694	MESH:D011618
33362607	Association	MESH:D003072	3559
33362607	Association	MESH:D003072	3586
33362607	Positive_Correlation	MESH:D008694	MESH:D007922
33362607	Association	MESH:D011618	3559
33362607	Association	MESH:D011618	3586
33362607	Association	MESH:D008694	3586

